The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates

Author:

Kiely Belinda E.1,Martin Andrew J.1,Tattersall Martin H.N.1,Nowak Anna K.1,Goldstein David1,Wilcken Nicholas R.C.1,Wyld David K.1,Abdi Ehtesham A.1,Glasgow Amanda1,Beale Philip J.1,Jefford Michael1,Glare Paul A.1,Stockler Martin R.1

Affiliation:

1. Belinda E. Kiely, Andrew J. Martin, and Martin R. Stockler, National Health and Medical Research Council Clinical Trials Centre, University of Sydney; Belinda E. Kiely, Martin H.N. Tattersall, Nicholas R.C. Wilcken, Philip J. Beale, and Martin R. Stockler, Sydney Medical School, University of Sydney; Belinda E. Kiely, Martin H.N. Tattersall, Philip J. Beale, and Martin R. Stockler, Sydney Cancer Centre–Royal Prince Alfred and Concord Hospitals, Sydney; David Goldstein, Prince of Wales Hospital Clinical...

Abstract

PurposeTo determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer.Patients and MethodsTwenty-one oncologists estimated the “median survival of a group of identical patients” for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression.ResultsMedian survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, ≤ one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101U/L (HR = 2.8; P = .0002), Karnofsky performance status ≤ 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02).ConclusionOncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3